Skip Navigation
Menu
Editorials |20 June 2006

Abatacept in Rheumatoid Arthritis: A New Branch on the “Biologics” Tree

Maarten Boers, MSc, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From VU University Medical Center, Amsterdam, the Netherlands.

    Potential Financial Conflicts of Interest: Consultancies: Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Genentech/Roche, Nitec Pharma, Johnson & Johnson, Wyeth, Shionogi, Pfizer, Savient; Grants received: OMERACT.

    Current Author Address: Maarten Boers, MSc, MD, PhD, Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands.

×
FULL TEXT
In the last 2 decades, rheumatology has become a field with high yield potential for drug developers, and the complex diseases that rheumatologists treat have come under intense scrutiny. Targeting tumor necrosis factor (TNF) and its receptor by monoclonal antibodies has become a highly successful treatment for rheumatoid arthritis (RA) and a growing list of other diseases. Ongoing research is increasing both our knowledge of (patho)immunology and our treatment options. Once the dust has settled, science historians will doubtless find many research opportunities in the almost yearly change of paradigms of autoimmune disease.
In this issue, the third and pivotal phase III trial of abatacept in RA by Kremer and colleagues (1) marks the coming of age of a new therapeutic pathway, based on the inhibition of full T-cell activation. Strong points of the trial include state-of-the-art trial procedures, large sample size, and meticulous attention to handling missing data. On the basis of this and other trials, the U.S. Food and Drug Administration (FDA) recently approved abatacept, saying that it reduces signs and symptoms, slows joint damage, and improves physical function in active RA, which has responded inadequately to disease-modifying drugs, such as methotrexate or TNF antagonists (2, 3). The last 2 words are important: Abatacept is the first drug to receive a label referring to TNF antagonists. Because of safety concerns expressed at the FDA advisory board meeting (mainly about severe infections and cancer), the company producing the drug has implemented an extensive pharmacovigilance program (4).
FULL TEXT
PDF
Not Available
Citations
Citation

Boers M. Abatacept in Rheumatoid Arthritis: A New Branch on the “Biologics” Tree. Ann Intern Med. ;144:933–935. doi: 10.7326/0003-4819-144-12-200606200-00012

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2006;144(12):933-935.

DOI: 10.7326/0003-4819-144-12-200606200-00012

©
2006 American College of Physicians
12 Citations

Related Articles
Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis
Annals of Internal Medicine; 167 (1): 8-16
Cost-Effectiveness of Biologics as First-Line Treatment of Rheumatoid Arthritis: Case Closed?
Annals of Internal Medicine; 151 (9): 668-669
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial
Annals of Internal Medicine; 144 (12): 865-876
Abatacept for People with Active Rheumatoid Arthritis
Annals of Internal Medicine; 144 (12): I-18
View MoreView Less

Journal Club
In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
Patients with new-onset rheumatoid arthritis had increased risk for ischemic and nonischemic heart failure
Annals of Internal Medicine; 167 (2): JC8
Review: In rheumatoid arthritis, TNF-α inhibitors do not differ from placebo or DMARDs for all-cause mortality
Annals of Internal Medicine; 164 (4): JC20
Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes
Annals of Internal Medicine; 162 (12): JC9
View MoreView Less

Related Point of Care
Rheumatoid Arthritis
Annals of Internal Medicine; 153 (1): ITC1-1
View MoreView Less

Related Topics
Rheumatoid Arthritis
Rheumatology

Rheumatoid Arthritis, Rheumatology.

PubMed Articles
Characterization of Volatile Organic Compound (VOC) metabolites in Cigarette smokers, Electronic Nicotine Device Users, Dual Users and Non- users of tobacco.
Nicotine Tob Res 2019.
Understanding the role of intermolecular interactions between lissoclimides and the eukaryotic ribosome.
Nucleic Acids Res 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×